MedPath

Folic acid

Generic Name
Folic acid
Brand Names
Animi-3 With Vitamin D, Citranatal B-calm Kit, Citranatal Harmony, Concept Ob, EnBrace HR, EnLyte, Ferralet 90, Folbic, Foltabs, Hematogen, Infuvite, Infuvite Pediatric, Irospan 24/6 Kit, Magnebind 400 Rx, Mvc-fluoride, Mvi Pediatric, Natafort, Nicomide, Pregvit, Tandem Plus, Vitafol-one
Drug Type
Small Molecule
Chemical Formula
C19H19N7O6
CAS Number
59-30-3
Unique Ingredient Identifier
935E97BOY8
Background

Folic acid, also known as folate or Vitamin B9, is a member of the B vitamin family and an essential cofactor for enzymes involved in DNA and RNA synthesis. More specifically, folic acid is required by the body for the synthesis of purines, pyrimidines, and methionine before incorporation into DNA or protein. Folic acid is particularly important during phases of rapid cell division, such as infancy, pregnancy, and erythropoiesis, and plays a protective factor in the development of cancer. As humans are unable to synthesize folic acid endogenously, diet and supplementation is necessary to prevent deficiencies. For example, folic acid is present in green vegetables, beans, avocado, and some fruits.

In order to function within the body, folic acid must first be reduced by the enzyme dihydrofolate reductase (DHFR) into the cofactors dihydrofolate (DHF) and tetrahydrofolate (THF). This important pathway, which is required for de novo synthesis of nucleic acids and amino acids, is disrupted by anti-metabolite therapies such as Methotrexate as they function as DHFR inhibitors to prevent DNA synthesis in rapidly dividing cells, and therefore prevent the formation of DHF and THF. When used in high doses such as for cancer therapy, or in low doses such as for Rheumatoid Arthritis or psoriasis, Methotrexate impedes the body's ability to create folic acid. This results in a deficiency of coenzymes and a resultant buildup of toxic substances that are responsible for numerous adverse side effects. As a result, supplementation with 1-5mg of folic acid is recommended to prevent deficiency and a number of side effects associated with MTX therapy including mouth ulcers and gastrointestinal irritation. Leucovorin (also known as folinic acid) supplementation is typically used for high-dose MTX regimens for the treatment of cancer. Levoleucovorin and leucovorin are analogs of tetrahydrofolate (THF) and are able to bypass DHFR reduction to act as a cellular replacement for the co-factor THF.

There are also several antiepileptic drugs (AEDs) that are associated with reduced serum and red blood cell folate, including Carbamazepine (CBZ), Phenytoin (PHT), or barbiturates. Folic acid is therefore often provided as supplementation to individuals using these medications, particularly to women of child-bearing age.

Inadequate folate levels can result in a number of health concerns including cardiovascular disease, megaloblastic anemias, cognitive deficiencies, and neural tube defects (NTDs). Folic acid is typically supplemented during pregnancy to prevent the development of NTDs and in individuals with alcoholism to prevent the development of neurological disorders, for example.

Indication

Folic acid is indicated for the treatment of folic acid deficiency, megaloblastic anemia, and in anemias of nutritional origins, pregnancy, infancy, or childhood.

Associated Conditions
Anaemia folate deficiency, Folate deficiency, Iron Deficiency (ID), Iron Deficiency Anemia (IDA), Latent Iron Deficiency, Neural Tube Defects (NTDs), Vitamin Deficiency, Methotrexate toxicity
Associated Therapies
Nutritional supplementation

Folate Receptor Alpha Dendritic Cells (FRαDCs) or Placebo for the Treatment of Patients with Stage III or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer, FAROUT Trial

Phase 2
Recruiting
Conditions
Advanced Fallopian Tube Carcinoma
Advanced Fallopian Tube High Grade Serous Adenocarcinoma
Advanced Ovarian Carcinoma
Advanced Ovarian Carcinosarcoma
Advanced Ovarian Clear Cell Adenocarcinoma
Advanced Ovarian Endometrioid Adenocarcinoma
Advanced Ovarian High Grade Serous Adenocarcinoma
Advanced Primary Peritoneal Carcinoma
Advanced Primary Peritoneal High Grade Serous Adenocarcinoma
Fallopian Tube Carcinosarcoma
Interventions
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Biological: Diphtheria Toxoid/Tetanus Toxoid/Acellular Pertussis Vaccine Adsorbed
Procedure: Leukapheresis
Procedure: Magnetic Resonance Imaging
Drug: Placebo Administration
First Posted Date
2024-10-15
Last Posted Date
2025-03-06
Lead Sponsor
Mayo Clinic
Target Recruit Count
78
Registration Number
NCT06639074
Locations
🇺🇸

Mayo Clinic in Arizona, Scottsdale, Arizona, United States

🇺🇸

Mayo Clinic in Florida, Jacksonville, Florida, United States

🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

Efficacy and Safety of Weifuchun Tablet in Reversing Gastric Intestinal Metaplasia

Phase 4
Not yet recruiting
Conditions
Gastric Intestinal Metaplasia
Interventions
First Posted Date
2024-09-24
Last Posted Date
2024-09-24
Lead Sponsor
Yongquan Shi
Target Recruit Count
400
Registration Number
NCT06610266

of Myo-inositol, Melatonin and Co-enzyme q10 on Ovarian Reserve

Phase 3
Not yet recruiting
Conditions
IVF
Interventions
Drug: Co-Enzyme Q10
Drug: Myoinositol
First Posted Date
2024-05-08
Last Posted Date
2024-05-08
Lead Sponsor
Beni-Suef University
Target Recruit Count
200
Registration Number
NCT06405204
Locations
🇪🇬

Beni-suef university Hospital, Banī Suwayf, Egypt

Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia

Phase 4
Not yet recruiting
Conditions
Hypophosphatasia
Interventions
First Posted Date
2023-08-29
Last Posted Date
2025-02-18
Lead Sponsor
Alexion Pharmaceuticals, Inc.
Target Recruit Count
8
Registration Number
NCT06015750
Locations
🇬🇧

Research Site, Manchester, United Kingdom

Effect of Folic Acid in Levodopa Treated Parkinson's Disease Patients

Phase 2
Recruiting
Conditions
Parkinson Disease
Interventions
First Posted Date
2023-07-25
Last Posted Date
2023-09-26
Lead Sponsor
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh
Target Recruit Count
60
Registration Number
NCT05959044
Locations
🇧🇩

BSMMU, Dhaka, Bangladesh

Myoinositol Effect on Asprosin Levels

Not Applicable
Completed
Conditions
Pregnancy Related
Interventions
Drug: myoinositol and folic acid
First Posted Date
2023-07-13
Last Posted Date
2023-07-13
Lead Sponsor
Near East University, Turkey
Target Recruit Count
40
Registration Number
NCT05943158
Locations
🇨🇾

Near East University Faculty of Medicine, Nicosia, Cyprus

Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Phase 1
Suspended
Conditions
Fallopian Tube Carcinosarcoma
Primary Peritoneal Carcinosarcoma
Recurrent Fallopian Tube Carcinoma
Recurrent Fallopian Tube Clear Cell Adenocarcinoma
Recurrent Fallopian Tube Endometrioid Adenocarcinoma
Recurrent Fallopian Tube High Grade Serous Adenocarcinoma
Recurrent Ovarian Carcinoma
Recurrent Ovarian Carcinosarcoma
Recurrent Ovarian Clear Cell Adenocarcinoma
Recurrent Ovarian Endometrioid Adenocarcinoma
Interventions
Procedure: Biopsy
Procedure: Biospecimen Collection
Procedure: Computed Tomography
Procedure: Magnetic Resonance Imaging
Procedure: Pheresis
First Posted Date
2023-06-27
Last Posted Date
2025-04-21
Lead Sponsor
Mayo Clinic
Target Recruit Count
40
Registration Number
NCT05920798
Locations
🇺🇸

Mayo Clinic in Arizona, Scottsdale, Arizona, United States

🇺🇸

Mayo Clinic in Florida, Jacksonville, Florida, United States

🇺🇸

Mayo Clinic in Rochester, Rochester, Minnesota, United States

Folic Acid Supplementation in Calcific Aortic Valve Disease

Phase 2
Not yet recruiting
Conditions
Calcification of Aortic Valve
Aortic Valve Stenosis
Interventions
Dietary Supplement: Placebo
First Posted Date
2023-05-17
Last Posted Date
2023-05-17
Lead Sponsor
Wuhan Union Hospital, China
Target Recruit Count
100
Registration Number
NCT05861648

Quintuple Method for Treatment of Multiple Refractory Colorectal Liver Metastases

Phase 2
Not yet recruiting
Conditions
For Patients With Colorectal Cancer Liver Metastases Who Were Not Able to Curative Surgical Resection.Focused on the Treatment Effect With the Quintuple Method
Interventions
First Posted Date
2023-03-20
Last Posted Date
2023-03-20
Lead Sponsor
Liaoning Tumor Hospital & Institute
Target Recruit Count
100
Registration Number
NCT05774964
Locations
🇨🇳

Liaoning Tumor Hospital & Institute, Shenyang, Liaoning, China

Early Blocking Strategy for Metachronous Liver Metastasis of Colorectal Cancer Based on Pre-hepatic CTC Detection

Phase 2
Not yet recruiting
Conditions
Preventive Effect of Quintuple Therapy on Metachronous Liver Metastases in Patients With Colorectal Cancer
Interventions
First Posted Date
2023-02-09
Last Posted Date
2023-02-09
Lead Sponsor
Liaoning Tumor Hospital & Institute
Target Recruit Count
100
Registration Number
NCT05720559
© Copyright 2025. All Rights Reserved by MedPath